Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €12.82 EUR
Change Today -0.13 / -1.00%
Volume 9.0K
CLNV On Other Exchanges
EN Paris
As of 11:35 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

cellnovo group sa (CLNV) Snapshot

Previous Close
Day High
Day Low
52 Week High
07/16/15 - €15.40
52 Week Low
07/10/15 - €10.63
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for CELLNOVO GROUP SA (CLNV)

Related News

No related news articles were found.

cellnovo group sa (CLNV) Related Businessweek News

No Related Businessweek News Found

cellnovo group sa (CLNV) Details

Cellnovo Limited, a medical technology company, develops and markets mobile diabetes management systems. The company’s mobile diabetes management system includes insulin patch pumps, and activity monitors, as well as cellular enabled wireless touchscreen handsets with integrated blood glucose meters and automatic connectivity to the cloud. Its touchscreen headset device is used for monitoring blood glucose, insulin, carbohydrate intake, and intensity and timing of daily activity, as well as for automatically recording insulin, blood glucose, food, and exercise related information. The company markets its insulin patch pump systems via a direct sales force in the United Kingdom and France, as well as through distributors internationally. Cellnovo Limited is based in Swansea, United Kingdom.

75 Employees
Last Reported Date: 03/2/15

cellnovo group sa (CLNV) Top Compensated Officers

Executive Chairman
Total Annual Compensation: €173.3K
Compensation as of Fiscal Year 2014.

cellnovo group sa (CLNV) Key Developments

Cellnovo Limited Hires Senior Management Team; Opens New Subsidiary in France with an Office in Paris

Cellnovo Limited announced the appointments of three executives to the senior management team. Bart Bergstein has been appointed as Chief Financial Officer, Steve Bubrick as Vice President Global Marketing and Business Development, and Didier Moire as Area Director of newly created Cellnovo France. Bart Bergstein has a 24 year track record in the financial industry including 14 years in Venture Capital. After joining the private equity arm of ABN AMRO in 1997, Bart established the AMRO Life Sciences Team that later spun out as Forbion Capital Partners. Steve Bubrick has more than 20 years of experience in the diabetes industry. He joins Cellnovo from Asante Solutions where he held the position of Vice President Commercial Operations. Prior to Asante, Steve held senior commercial positions at Insulet, Abbott, Therasense and Lifescan where he was involved in bringing disruptive monitoring and insulin delivery products to markets worldwide. Steve will also be in charge of laying the foundations of Cellnovo's business in North America, starting with overseeing its regulatory filing process. Recognizing the importance of the diabetes market in France, Cellnovo has created a subsidiary in the country with an office in Paris, where Didier Moire will be based and responsible for sales in France, Belgium and Luxembourg. Didier has more than 25 years' experience in Medical Technology and Diagnostics. He was previously Managing Director France/Benelux for Immucor and also held senior positions in Chiron and Novartis.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CLNV:FP €12.82 EUR -0.13

CLNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CLNV.
View Industry Companies

Industry Analysis


Industry Average

Valuation CLNV Industry Range
Price/Earnings -- Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow -- Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELLNOVO GROUP SA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at